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infections (Ramsay et al., 1993; Guidotti and Chisari,
1996; Ramshaw et al., 1997; Biron, 1999). In vivo, these
cytokines play a role in controlling the growth of several
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viruses including Semliki forest virus, Theiler's virus,La Jolla, California 92037
vaccinia virus, herpes simplex virus, measles virus, influ-
enza virus, hepatitis B virus, murine cytomegalovirus,
and to a degree, lymphocytic choriomeningitis virusCD81 T lymphocytes control microbial infections in two
(LCMV) (Bouley et al., 1995; Fiette et al., 1995; Finke etgeneral ways: by secreting cytokines, such as IFNg and
al., 1995; Hwang et al., 1995; van den Broek et al., 1995a,TNFa, and by lysing infected cells via the perforin or
1995b; Guidotti and Chisari, 1996; Topham et al., 1996;Fas/FasL pathways. These two functions differ in that
Tay and Welsh, 1997). This indicates that cytokines cancytokine release can have both local and systemic con-
play a role in limiting infections by both lytic and non-sequences, whereas cell lysis is limited to target cells
lytic viruses. Although LCMV can be cleared noncyto-that are in direct contact with the T cell. It has been
pathically from some cells (e.g., hepatocytes) (Guidottigenerally assumed that for controlling viral infections,
et al., 1999a), complete clearance of nonlytic virusesthe cytolytic function of CD81 T cells far outweighed
such as LCMV often requires perforin-mediated lysis of
the contribution made by their release of cytokines. infected cells (Kagi et al., 1994; Walsh et al., 1994). In
However, several studies have shown that exposure to contrast, perforin-mediated lysis may be less important
cytokines can directly reduce viral replication and, in in controlling infection by lytic viruses, since these
some cases, cytokines alone are able to ªcureº infected agents inevitably destroy their host cells during their
cells by inactivating viral replication in the absence of replicative cycle (Kagi et al., 1996). The remarkable find-
cell death (Guidotti and Chisari, 1996; Estcourt et al., ing that cytokines can abolish viral replication without
1998). This indicates that target cell lysis and cytokine cytolysis (e.g., LCMV and HBV replication in hepato-
production play complementary roles in controlling in- cytes) (Guidotti et al., 1996, 1999a, 1999b) demonstrates
fection. However, T cell±mediated control of virus infec- an example of the ultimate antiviral defense strategy;
tion can be costly to the host, because it is almost the invading pathogen is eradicated without the expense
inevitably accompanied by some degree of immunopa- of destroying the infected host cell.
thology. In many viral infections, signs and symptoms How is viral replication blocked without harming the
worsen even as viral titers decline, resulting from the infected cell? In vitro experiments have shown that di-
host's immune response to the virus rather than from the rect exposure to cytokines such as the interferons or
destructive effects of the virus per se. This minireview TNFa/b induces cellular proteins that can decrease tran-
focuses on cytokine release; the immunopathological scription and/or replication of several viruses including
sequelae of perforin-mediated lysis, although some- influenza, VSV, HSV, adenovirus, encephalomyocarditis
times serious (Gebhard et al., 1998), will not be further virus, and parainfluenza virus (Horisberger et al., 1983;
discussed herein. Mestan et al., 1986; Wong and Goeddel, 1986; Kumar
Production of inflammatory cytokines in response to et al., 1988; Staeheli and Pavlovic, 1991; Zhao et al.,
infection can cause immunopathology that ranges from 1996). Some of the most extensively studied cellular
minor (e.g., low-grade fever) to severe (e.g., organ failure proteins that mediate these responses are double-
and death). How do T cells maintain a balance between stranded RNA activated protein kinase (PKR), 29-59-oli-
antiviral efficacy and the hazards of unbridled cytokine goadenylate synthetase (2±5OAS), dsRNA-specific aden-
release? Antigen-specific T cells have developed regula- osine deaminase (dsRAD), and MxA (Katze, 1995;
tory mechanisms that allow them to very rapidly turn on Boehm et al., 1997; Haller et al., 1998; Rebouillat and
and turn off cytokine production in direct response to Hovanessian, 1999). PKR and 2±5OAS are expressed at
antigen contact. Although the molecular mechanisms a relatively low constitutive level in many cell types, but
are not fully understood, this strategy focuses the pro- their expression is greatly increased upon exposure to
duction of antiviral cytokines specifically to sites of in- IFNa, IFNg, or a combination of both types of interferon.
fection and reduces the immunopathology that would Likewise, the steady state levels of dsRAD are increased
occur if these inflammatory mediators were chronically after exposure to either type I or type II interferon. MxA
released or secreted in inappropriate anatomic loca- protein is induced by type I interferons and provides
tions. innate resistance against a large number of RNA viruses
including orthomyxoviruses, bunyaviruses, phlebovi-
ruses, and hantaviruses (Frese et al., 1996).Role of Cytokines in Controlling Viral Infection
The importance of cytokines in orchestrating the im-
Several approaches have been used to determine the mune response to viral infections is, perhaps, best em-
role of cytokines in immune defense. Depletion of cyto- phasized by the extraordinary lengths to which viruses
kines in vivo with antibodies, the use of knockout mice have gone to circumvent their effects; many viruses ex-
deficient in specific cytokines or cytokine receptors, and press molecules designed to counter or to misdirect
recombinant viruses engineered to express specific cy- host cytokines (Kalvakolanu, 1999). For example, Ep-
tokines have led to a greater appreciation of how impor- stein-Barr virus (EBV) produces a homolog of IL-10 that,
tant IFNa/b, IFNg, and TNFa are for controlling viral like its host counterpart, downregulates IFNg production
(Moore et al., 1993). Pox viruses encode genes that act
as TNFa and/or TNFb receptors, and deletion of these* To whom correspondence should be addressed (e-mail: lwhitton@
scripps.edu). genes results in decreased virulence in vivo, indicating
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that these ªviroceptorsº play a biologically significant ton, 2000a). However, upon encountering their cognate
antigen, many of these primary effector T cells initiaterole in the pathogenesis of these viruses (Spriggs, 1994;
cytokine production within 30±60 min, and essentiallySmith, 1996; Nash et al., 1999). Pox viruses also express
all of the virus-specific T cells produce cytokines withinproteins that bind IFNa, b, or g, and one viral IFNg bind-
4±6 hr (Slifka et al., 1999a).ing protein encoded by tanapoxvirus also appears to
Due to the problems associated with inappropriatebind IL-2 and IL-5 (Essani et al., 1994). The M-T7 protein
cytokine release (Slifka and Whitton, 2000b), it is impor-of myxoma virus also has multiple functions and binds
tant that T cell±mediated cytokine production be strictlyrabbit IFNg in addition to several chemokines (Mossman
regulated. To determine how quickly primary effector Tet al., 1996). These viral evasion strategies provide indi-
cells could terminate cytokine production following lossrect, yet compelling, evidence for the importance of
of antigen contact, IFNg synthesis by virus-specificcytokines in antiviral immune defense.
CD81 T cells was monitored after removal of peptide-
coated APCs (Slifka et al., 1999a). Strikingly, if T cell:APCDangers of Uncontrolled Cytokine Production
contact is disrupted and the APCs are removed fromAlthough cytokines are important in protecting against
the cultures, then the number of cytokine-producing Tinfection, many are toxic or even lethal at high concen-
cells drops precipitously, at a rate similar to that ob-trations. For example, injection of bacterial endotoxin
served after adding cycloheximide, a protein synthesisinduces high serum levels of inflammatory cytokines
inhibitor. Cytokine production is not permanently abro-such as TNFa, IL-12, and IFNg (Beutler et al., 1985;
gated after loss of antigen contact; instead, addition ofOzmen et al., 1994), and these cytokines, especially
fresh peptide to the cultures restores cytokine synthesisTNFa, are the primary mediators of mortality (Dinarello,
in essentially all of the antigen-specific cells, and the1996). Despite extensive research, the mortality rate in
kinetics of cytokine reinitiation are z5-fold faster thanhumans with septic shock remains at .30%, resulting in
those observed during the initial peptide stimulus. Fig-more than 100,000 deaths annually in the United States
ure 1 schematically displays four key features of cyto-alone (Baumgartner and Glauser, 1993; Bone et al., 1995;
kine regulation by primary effector CD81 T cells duringCross et al., 1999). Evidence for the remarkable toxicity
virus infection. (1) Most virus-specific CD81 T cells doof certain cytokines can be gathered from animal studies
not constitutively produce cytokines when analyzed di-(Carson et al., 1999; Cousens et al., 1999), and from
rectly ex vivo. (2) Cytokine synthesis is quickly initiatedhuman clinical trials in which individual cytokines have
upon antigen contact, and plateaus z5 hr later, whenbeen administered at high doses (Demetri et al., 1989;
almost all virus-specific cells are producing cytokines.Leonard et al., 1997). For example, intravenous injection
(3) Cytokine production terminates immediately follow-of a high dose of TNFa results in toxicity that is similar
ing the loss of antigen contact. (4) Restoration of antigento septicemic shock, including fever, hypotension, acute
contact induces a second wave of cytokine synthesis,tubular necrosis, metabolic acidosis, hepatic dysfunc-
demonstrating that CD81 T cells can cycle cytokine pro-tion, and respiratory failure (Jones and Selby, 1989).
duction on, off, and on again in rapid succession.Similarly, high doses of IL-2 induce respiratory distress
The above discussion applies to primary effector
and vascular leakage, which severely restricts its thera- CD81 T cells, but many of the observed responses apply
peutic use in humans (Tartour et al., 1992). It has been also to CD81 memory T cells. After LCMV infection has
assumed that macrophages and other cells of the innate resolved, T cell responses decline to a plateau at which
immune system are responsible for LPS-induced cyto- virus-specific memory cells constitute z10% of the total
kine production, but a recent study has shown that en- CD81 T cell population (Butz and Bevan, 1998; Murali-
dotoxic shock is accelerated in virus-infected mice and Krishna et al., 1998; Slifka and Whitton, 2000a). The
may be due, at least in part, to aberrant cytokine produc- majority of these memory cells are small and have a
tion by T cells and NK cells (Nguyen and Biron, 1999). resting phenotype and, while some memory T cells are
Furthermore, it is clear that during viral infection, T cells cytolytic directly ex vivo (Selin and Welsh, 1997), these
can secrete sufficient quantities of cytokine to kill the cells usually require up to 24 hr for optimal lytic activity
host (Puglielli et al., 1999). Together, these studies dra- (Ehl et al., 1997; Bachmann et al., 1999a). In contrast to
matically illustrate how essential it is that the host main- the lag period in perforin-mediated lysis, memory T cells
tain strict regulation of T cell cytokine synthesis. rapidly initiate cytokine production following antigen
contact, with essentially the same kinetics as primary
Antigen-Specific Regulation of Cytokine Synthesis effector T cells (Slifka and Whitton, 2000a). Together,
Many viruses are able to produce infectious progeny these data suggest that cytokine release may be a par-
within 3±10 hr after binding to their target cell (Kagi ticularly important factor in the early antiviral immune
et al., 1996). This provides only a narrow window of response mounted in previously vaccinated hosts. Simi-
opportunity for virus-specific T cells to intervene and lar to primary effector T cells, loss of antigen contact
abrogate viral replication. How quickly can CD81 T cells results in the immediate termination of cytokine produc-
recognize infected targets and mount an antiviral re- tion by memory T cells (Slifka and Whitton, 2000a). How-
sponse? Studies using LCMV have indicated that pri- ever, in contrast to activated cells, after disruption of
mary effector CD81 T cells maintain appreciable levels antigen contact only a subpopulation of antigen-specific
of intracellular perforin and can begin lysing infected memory T cells is able to reinitiate IFNg production when
targets within 60 min in the absence of de novo protein peptide antigen is restored (Figure 1, dotted green line).
synthesis (Slifka et al., 1999a, 1999b). Several groups It is not known if these cells become apoptotic or aner-
have shown that in contrast to perforin expression, ac- gic, but we should not necessarily conclude that mem-
tively cytolytic antigen-specific CD81 T cells do not ex- ory T cells are defective in their ability to respond to
press cytokines directly ex vivo even at the peak of the repeated antigen contact. Perhaps a certain proportion
antiviral immune response (Flynn et al., 1998; Murali- of memory T cells produce IFNg only when first reex-
posed to antigen and, after antigen disengagement andKrishna et al., 1998; Slifka et al., 1999a; Slifka and Whit-
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Figure 1. Rapid On/Off/On Cycling of Cytokine Production by Virus-Specific T Cells
Induction of antigen-specific cytokine production is essentially identical in both activated and memory T cell populations (dashed blue line).
Prior to antigen contact, very few CD81 T cells express IFNg. However, after antigen contact, nearly all of the responding T cells are producing
cytokine within 4±6 hr, and cytokine production is then maintained as long as the cells remain in direct contact with antigen. Loss of antigen
contact leads to the rapid termination of cytokine production (red and green lines) and is as rapid as that observed following addition of a
potent protein synthesis inhibitor, cycloheximide (CHX; gray line). If peptide antigen is restored to cells shortly after disruption of antigen
contact, cytokine production quickly resumes (green lines). Although essentially all of the primary effector T cells resume cytokine synthesis
(solid green line), only a sub-population of virus-specific memory cells reinitiates IFNg production (dotted green line). This figure summarizes
data from previously published work (Slifka et al., 1999a; Slifka and Whitton, 2000a).
reengagement, may instead initiate synthesis of other what downstream events are required for cytokine pro-
duction? The rapid induction of cytokine synthesis bycytokines or of antiviral products such as perforin. Alter-
natively, they may enter the cell cycle, which would virus-specific T cells requires transcription, since addi-
tion of actinomycin D prior to peptide stimulation com-benefit the host by providing an expanded population
of antigen-specific T cells. pletely abrogates IFNg production in vitro (Slifka et al.,
1999a). It is tempting to suggest that the 5-fold more
rapid cytokine response seen during antigen-specificMolecular Aspects of Cytokine Regulation
on/off/on cycling (Figure 1, green line) might be facili-The molecular basis of T cell activation has been exten-
tated by the short-term retention of cytokine mRNA.sively studied (Clements et al., 1999; Schraven et al.,
Cytokine mRNAs are notoriously unstable (Sachs, 1993;1999) and begins when the TcR comes into contact with
Ross, 1995; Laroia et al., 1999), but CD3/CD28 coen-agonistic peptide presented on the appropriate MHC
gagement appears to increase the stability of thesemolecule. Almost immediately after TcR engagement,
mRNAs (Lindstein et al., 1989). Thus, we speculate thatthere is tyrosine phosphorylation of CD3-associated
the mRNA-stabilizing effect of TcR/CD28 engagementproteins, followed by the recruitment of ZAP-70 and
temporarily permits antigen-specific T cells to respondthe activation of the phosphatidylinositol pathway. This
more rapidly to the repeated antigen contact that mayresults in increased levels of intracellular calcium and
occur at sites of infection.protein kinase C activation. Recent evidence indicates
Compared to T cell activation, less is known aboutthat T cell activation may be greatly facilitated by sphin-
the molecular events that take place after the TcR disen-golipid- and cholesterol-enriched membrane microdo-
gages from its ligand. Antigen removal, or the additionmains called rafts, which concentrate many signaling
of anti-MHC antibodies, results in termination of signalcomponents such as Lck and Lak (Simons and Ikonen,
transduction (as measured by Ca21 mobilization or acid1997; Moran and Miceli, 1998; Zhang et al., 1998) and
production) within as few as 2±4 min (Valitutti et al.,recruit triggered TcRs (Montixi et al., 1998; Xavier et al.,
1995; Beeson et al., 1996) and, as discussed above,1998). The speed with which CD81 T cells respond to
disruption of TcR stimulation by removal of peptide anti-viral peptide antigens implies rapid signal transduction,
gen results in the immediate loss of cytokine production.which may be accelerated by the presence of preex-
This is consistent with the hypothesis that continualisting signal transduction proteins (Bachmann et al.,
stimulation is needed to maintain cytokine synthesis. Is1999b) and/or the accumulation of surface-associated
the rapid cessation of TcR signaling due to the passiverafts (Viola and Lanzavecchia, 1999; Viola et al., 1999).
After a signal has been transduced through the TcR, degradation of the signaling complex, or is it actively
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Figure 2. Consequences of Cytokine Secretion by Virus-Specific CD81 T Cells
As CD81 T cells migrate through the bloodstream and uninfected tissues, they are in surveillance mode and do not express cytokine mRNA
or cytokine proteins. In contrast, activated T cells do express sufficient amounts of intracellular perforin to lyse infected target cells upon
contact without requiring de novo protein synthesis (Slifka et al., 1999b). When the T cell comes into contact with an infected cell, it immediately
switches from surveillance mode to effector mode, and cytokine production is initiated within minutes (Slifka et al., 1999a). Three consequences
of effector function are illustrated.
(A) The activated T cell destroys the infected target cell through the release of perforin, thus preventing maturation of viral particles.
(B) Cytokine production by virus-specific T cells occurs only when the T cell is in direct contact with an infected target cell. This ensures that
cytokines are produced only in the vicinity of infected cells. In at least some cases (see text), cytokines appear to eradicate the virus without
harming the cell, which thus is cured of infection. However, as indicated by ª?º, cytokines will not always be able to cure cells of infection.
Some cell types may be unresponsive to cytokines (perhaps lacking the appropriate receptors), and/or some viruses may be resistant to the
direct effects of antiviral cytokines.
(C) The high local concentration of antiviral cytokines affects nearby uninfected cells. MHC class I expression is upregulated so that, if the
cell becomes infected, it will quickly be recognized by virus-specific T cells; this maximizes the antiviral effect of perforin-mediated lysis. In
addition, the uninfected cells will upregulate cellular genes known to increase resistance to viral infection (e.g., dsRAD and 2±5OAS). As virus
is cleared from infected cells, the T cell loses contact with stimulatory antigen and immediately reverts to surveillance mode, terminating
cytokine production within minutes and thus minimizing unnecessary immunopathology.
dismantled by some type of downregulatory mecha- Model of In Vivo Cytokine Production
Based on the antigen-specific on/off/on regulation ofnism(s)? There is evidence to suggest that some adaptor
proteins such as cbl, SLAP-130, and SIT may interfere CD81 T cells observed directly ex vivo, we suggest that
similar mechanisms of cytokine regulation exist in vivowith TcR signaling. Overexpression of Cbl in a T cell line
decreases AP-1 activation (Rellahan et al., 1997) and (Figure 2). Thus, even at the peak of the antiviral immune
response, the vast majority of virus-specific CD81 Tmay block the activation of Ras by sequestering Grb2
(Meisner et al., 1995). In contrast, absence of Cbl-b ex- cells are ªsilentº in terms of cytokine production. During
migration through the circulation and inflamed tissues,pression results in increased production of IL-2 (Chiang
et al., 2000) and in generalized autoimmunity character- highly activated virus-specific T cells are in surveillance
mode and do not actively produce or secrete cytokines.ized by T and B lymphocyte infiltration of multiple organs
(Bachmaier et al., 2000). SLAP-130 has been shown to Recognition of the correct peptide sequence bound to
MHC class I would trigger the T cell to switch fromabrogate SLP-76-mediated augmentation of TcR-depen-
dent NF-AT activation, and, likewise, overexpression surveillance mode to effector mode, in which an acti-
vated CD81 T cell would deliver a lethal hit to the infectedof SIT (Marie-Cardine et al., 1999) inhibits activation of
NF-AT (Musci et al., 1997). It is possible that after loss target cell via the transfer of perforin granules and, in
parallel, would initiate antiviral cytokine production. Itof antigen contact, these potential downregulatory pro-
teins may sequester or inactivate different components is important to note that, although memory T cells take
longer than activated T cells to effectively lyse targetsof the signaling machinery in order to rapidly disengage
downstream activation events. (Ehl et al., 1997; Selin and Welsh, 1997; Bachmann et
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al., 1999a), they produce IFNg and TNFa with kinetics important therapeutic targets in cases of aberrant cyto-
almost identical to those observed in activated T cells kine production.
(Slifka and Whitton, 2000a). It is unlikely that CD81 T
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